San Diego-dependent Viking Therapeutics marked itself as a significant competitor from the weight loss drug market place in February right after revealing promising information from a mid-stage demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when given to be a weekly injection and in March the